Figure 6. Therapeutic vaccination against h5T4 benefits significantly from the combination with PD-1 antibody compared to other checkpoint inhibitors.

C57BL/6 mice were challenged subcutaneously with 0.5*10⁶ B16.h5T4 cells and immunised intramuscularly with 10⁷ IU of ChAdOx1.h5T4 the same day. A week later, mice were boosted with 10⁶ pfu of MVA.h5T4 and treated intratumourally with PD-1, PD-L1, LAG-3 antibodies or a combination of all three as described in M&M. Control mice were challenged with tumour cells but were left unvaccinated (naïve). Tumour size was measured three times per week and volumes were calculated as described above. Representative data of two biological replicate experiments are shown. (A) Tumour growth kinetics for each group expressed by mean tumour volume ± SEM. (B) Tumour volumes of each individual group at day 13 post B16.h5T4 challenge. Bars represent median. (C) Kaplan-Meyer survival curves of the different groups of mice and (D) statistical analyses for each group evaluated by the log-rank assay. Significant p values are shown.